ArticleDrug delivery and translational research2025
Lipid-based nanocarriers for enhanced gentamicin delivery: a comparative study of liquid crystal nanoparticles and liposomes against Escherichia coli biofilms.
Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Luminescent Nanocomposites of Liquid Crystals and Carbon Dots in Microfluidic Channels: Effects of Walls, Dynamics, and Bioactive Additive.Nanomaterials (Basel, Switzerland) · 2026Article
- Leciplex Nanocarriers: An Optimized Platform for Thymol Delivery in Acne Management.Pharmaceutics · 2026Article
- Enhanced nanoencapsulation of gentamicin, ciprofloxacin, and lysozyme in chitosan-MIL-53 metal-organic frameworks for a synergistic activity against drug-resistantRSC advances · 2026Article
- Electrically Charged Lipid Nanoparticles as Intracanal Antimicrobial Delivery Systems: A Narrative Review of Preclinical Evidence for Biofilm Control.Dentistry journal · 2026Review
- Ethosomal Nanocarriers for Hydrophilic Peptide Encapsulation: Formulation Optimization, Stability, and In Vitro Release Performance.Molecules (Basel, Switzerland) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional antibiotic therapies often fail to eradicate bacterial biofilms due to limited penetration, altered microenvironments, and the presence of persister cells, contributing to persistent and recurrent infections. As a result,the growing threat of antibiotic-resistant bacteria, particularly those forming biofilms, underscores the urgent need for alternative therapeutic strategies. Lipid-based drug delivery systems have emerged as effective nanocarriers for antimicrobials, offering a promising strategy to combat bacterial biofilms due to their biomimetic properties, biocompatibility, and ability to navigate the complex physical, chemical, and biological barriers posed by biofilms. In this study, we compared liquid crystal nanoparticles (LCNPs) and liposomes as delivery systems for gentamicin (GEN) against Escherichia coli (E. coli) (ATCC 25922 and ATCC 35218) in both planktonic and biofilm forms. Transmission electron microscopy analysis confirmed the particle size of GEN-loaded LCNPs (~ 200 nm) and GEN-loaded liposomes (~ 160 nm), with cubic-shaped LCNPs and lipid bilayer-structured liposomes which remained stable over three weeks at 4ºC. Loading GEN into lipid-based nanoparticles resulted in a two-fold reduction in minimum inhibitory concentration values, without significantly altering the minimum bactericidal concentration. Notably, GEN-LCNPs led to a significant fourfold (for E. coli ATCC 25922) and threefold (for E. coli ATCC 35218) reduction in inhibitory concentrations in biofilm states compared to unformulated GEN, achieving a minimum biofilm inhibitory concentration (MBIC) of 50 μg/mL and 100 μg/mL (P < 0.0001), respectively. In contrast, liposomes showed only a twofold reduction in MBIC values (100-150 μg/mL) for both bacterial biofilms. GEN-loaded LCNPs also reduced the E. coli ATCC 25922 colony-forming unit count by 5000-fold and 4000-fold, while liposomes with similar particle size did not significantly improve GEN's antimicrobial activity. Moreover, LCNPs improved GEN efficacy regardless of particle size or Pluronic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.